APT Medical (688617) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months of 2025 reached RMB 1.87 billion, up 22.47% year-over-year.

• Net profit attributable to shareholders was RMB 623.30 million, a 18.02% increase year-over-year.

• R&D investment rose 25.78% year-over-year, reflecting a focus on new products and technology.

Financial highlights

• Operating cash flow for the first nine months was RMB 676.06 million, up 29.06% year-over-year.

• Basic EPS for the first nine months was RMB 4.42, up from RMB 3.77 in the prior year.

• Gross margin improved as revenue growth outpaced cost increases.

• Total assets at quarter-end were RMB 3.46 billion, up 16.11% from the previous year-end.

Outlook and guidance

• Increased R&D spending signals continued investment in innovation and product pipeline.